Safety, Efficacy and a Simple Model to Predict Response of BNT162b2 mRNA
Safety, Efficacy and a Simple Model to Predict Response of BNT162b2 mRNA
On behalf of the Israel CLL study group the investigators will evaluate the efficacy and safety of BNT162b2 mRNA Covid-19 Vaccine in patients with chronic lymphocytic leukemia
Inclusion Criteria:
Exclusion Criteria:
ohadb.mail@gmail.com00972526669155